The MHRA and FDA are deepening cooperation on medical technology and AI, giving regulators a better chance to share expertise before the next miracle device arrives with a logo, a launch video and no answer to question three.
Medical AI meets the evidence box
The MHRA announcement sets out closer UK US work on medical technology regulation, alongside the National Commission on the Regulation of AI in Healthcare and planned international reliance routes. Those routes are intended to help some devices already assessed by trusted regulators reach the UK market more efficiently, while retaining proportionate safeguards.
That is useful cooperation, not a diplomatic shortcut through the clinical trial department. A device does not become safe because it crossed the Atlantic in a press release, and an algorithm does not become intelligent because its presentation included the word “transformative” six times.
MHRA and FDA give medical AI its homework
The new arrangements promise to reduce needless duplication and help manufacturers understand what regulators expect. They also leave everyone with the awkward task of demonstrating that a product works outside a beautifully lit conference hall.
The Institute of Respectful Algorithms has therefore introduced a pre launch assessment. Before any system may describe itself as revolutionary, it must answer three questions, complete a trial and stop glowing blue for ten consecutive minutes.
“The MHRA and FDA are asking medical AI to show its working,” said Dr Quentin Clipboard, Chair of the Committee for Asking One More Sensible Question. “This is devastating news for software that has previously relied on confidence, gradients and a very large annual report.”
International alignment could help useful tools reach clinicians sooner. It could also make it harder for manufacturers to treat every separate national form as an excuse to describe their product as trapped in bureaucracy.
At the first fictional joint demonstration, a presenter announced that the future had arrived. The screen share then requested permission to share the screen. The regulators invited it to explain its findings. It opened a blank cell and asked for an extension, becoming the first medical AI to demonstrate a convincing understanding of healthcare waiting lists.
Source: Medicines and Healthcare products Regulatory Agency.
